Therefore, a specific modulation of FXR signaling, liver and intestine-specific FXR agonist, intestine-specific FXR antagonist, can be a potential treatment of metabolic disorders, including non-alcoholic fatty liver disease [33]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.